Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 22

1.

Vaccines for Healthcare-associated Infections: Promise and Challenge.

Knisely JM, Liu B, Ranallo RT, Zou L.

Clin Infect Dis. 2016 Sep 1;63(5):657-62. doi: 10.1093/cid/ciw333. Epub 2016 May 20.

2.

Development of an Aotus nancymaae model for Shigella Vaccine immunogenicity and efficacy studies.

Gregory M, Kaminski RW, Lugo-Roman LA, Galvez Carrillo H, Tilley DH, Baldeviano C, Simons MP, Reynolds ND, Ranallo RT, Suvarnapunya AE, Venkatesan MM, Oaks EV.

Infect Immun. 2014 May;82(5):2027-36. doi: 10.1128/IAI.01665-13. Epub 2014 Mar 4.

3.

Oral administration of live Shigella vaccine candidates in rhesus monkeys show no evidence of competition for colonization and immunogenicity between different serotypes.

Ranallo RT, Kaminski R, Baqar S, Dutta M, Lugo-Roman LA, Boren T, Barnoy S, Venkatesan MM.

Vaccine. 2014 Mar 26;32(15):1754-60. doi: 10.1016/j.vaccine.2013.12.068. Epub 2014 Feb 9.

PMID:
24522159
4.

Self-adjuvanting bacterial vectors expressing pre-erythrocytic antigens induce sterile protection against malaria.

Bergmann-Leitner ES, Hosie H, Trichilo J, Deriso E, Ranallo RT, Alefantis T, Savranskaya T, Grewal P, Ockenhouse CF, Venkatesan MM, Delvecchio VG, Angov E.

Front Immunol. 2013 Jul 4;4:176. doi: 10.3389/fimmu.2013.00176. eCollection 2013.

5.

The ATP-dependent chromatin remodeling enzyme Fun30 represses transcription by sliding promoter-proximal nucleosomes.

Byeon B, Wang W, Barski A, Ranallo RT, Bao K, Schones DE, Zhao K, Wu C, Wu WH.

J Biol Chem. 2013 Aug 9;288(32):23182-93. doi: 10.1074/jbc.M113.471979. Epub 2013 Jun 18.

6.

The Shigella human challenge model.

Porter CK, Thura N, Ranallo RT, Riddle MS.

Epidemiol Infect. 2013 Feb;141(2):223-32. doi: 10.1017/S0950268812001677. Epub 2012 Aug 21. Review.

PMID:
22906296
7.

Two live attenuated Shigella flexneri 2a strains WRSf2G12 and WRSf2G15: a new combination of gene deletions for 2nd generation live attenuated vaccine candidates.

Ranallo RT, Fonseka S, Boren TL, Bedford LA, Kaminski RW, Thakkar S, Venkatesan MM.

Vaccine. 2012 Jul 20;30(34):5159-71. doi: 10.1016/j.vaccine.2012.05.003. Epub 2012 May 30.

PMID:
22658966
8.

Further characterization of Shigella sonnei live vaccine candidates WRSs2 and WRSs3-plasmid composition, invasion assays and Sereny reactions.

Bedford L, Fonseka S, Boren T, Ranallo RT, Suvarnapunya AE, Lee JE, Barnoy S, Venkatesan MM.

Gut Microbes. 2011 Jul-Aug;2(4):244-51. doi: 10.4161/gmic.2.4.17042. Epub 2011 Jul 1. No abstract available.

PMID:
21983066
9.

Safety and immunogenicity of an intranasal Shigella flexneri 2a Invaplex 50 vaccine.

Riddle MS, Kaminski RW, Williams C, Porter C, Baqar S, Kordis A, Gilliland T, Lapa J, Coughlin M, Soltis C, Jones E, Saunders J, Keiser PB, Ranallo RT, Gormley R, Nelson M, Turbyfill KR, Tribble D, Oaks EV.

Vaccine. 2011 Sep 16;29(40):7009-19. doi: 10.1016/j.vaccine.2011.07.033. Epub 2011 Jul 23.

PMID:
21787825
10.

Shigella sonnei vaccine candidates WRSs2 and WRSs3 are as immunogenic as WRSS1, a clinically tested vaccine candidate, in a primate model of infection.

Barnoy S, Baqar S, Kaminski RW, Collins T, Nemelka K, Hale TL, Ranallo RT, Venkatesan MM.

Vaccine. 2011 Aug 26;29(37):6371-8. doi: 10.1016/j.vaccine.2011.04.115. Epub 2011 May 17.

PMID:
21596086
11.

Osmoregulated periplasmic glucans synthesis gene family of Shigella flexneri.

Liu L, Dharne M, Kannan P, Smith A, Meng J, Fan M, Boren TL, Ranallo RT, Bhagwat AA.

Arch Microbiol. 2010 Mar;192(3):167-74. doi: 10.1007/s00203-009-0538-z.

PMID:
20062978
12.

Characterization of WRSs2 and WRSs3, new second-generation virG(icsA)-based Shigella sonnei vaccine candidates with the potential for reduced reactogenicity.

Barnoy S, Jeong KI, Helm RF, Suvarnapunya AE, Ranallo RT, Tzipori S, Venkatesan MM.

Vaccine. 2010 Feb 10;28(6):1642-54. doi: 10.1016/j.vaccine.2009.11.001. Epub 2009 Nov 20.

13.

Virulence, inflammatory potential, and adaptive immunity induced by Shigella flexneri msbB mutants.

Ranallo RT, Kaminski RW, George T, Kordis AA, Chen Q, Szabo K, Venkatesan MM.

Infect Immun. 2010 Jan;78(1):400-12. doi: 10.1128/IAI.00533-09. Epub 2009 Nov 2.

14.

Safety and colonization of two novel VirG(IcsA)-based live Shigella sonnei vaccine strains in rhesus macaques (Macaca mulatta).

Collins TA, Barnoy S, Baqar S, Ranallo RT, Nemelka KW, Venkatesan MM.

Comp Med. 2008 Feb;58(1):88-94.

15.

Immunogenicity and characterization of WRSF2G11: a second generation live attenuated Shigella flexneri 2a vaccine strain.

Ranallo RT, Thakkar S, Chen Q, Venkatesan MM.

Vaccine. 2007 Mar 8;25(12):2269-78. Epub 2006 Dec 20.

PMID:
17229494
16.

Live-attenuated Shigella vaccines.

Venkatesan MM, Ranallo RT.

Expert Rev Vaccines. 2006 Oct;5(5):669-86. Review.

PMID:
17181440
17.

Developing live Shigella vaccines using lambda Red recombineering.

Ranallo RT, Barnoy S, Thakkar S, Urick T, Venkatesan MM.

FEMS Immunol Med Microbiol. 2006 Aug;47(3):462-9.

18.

Mapping and functional characterization of the TAF11 interaction with TFIIA.

Robinson MM, Yatherajam G, Ranallo RT, Bric A, Paule MR, Stargell LA.

Mol Cell Biol. 2005 Feb;25(3):945-57.

20.

TFIIA interacts with TFIID via association with TATA-binding protein and TAF40.

Kraemer SM, Ranallo RT, Ogg RC, Stargell LA.

Mol Cell Biol. 2001 Mar;21(5):1737-46.

21.

Reevaluation of transcriptional regulation by TATA-binding protein oligomerization: predominance of monomers.

Campbell KM, Ranallo RT, Stargell LA, Lumb KJ.

Biochemistry. 2000 Mar 14;39(10):2633-8.

PMID:
10704213
22.

A TATA-binding protein mutant defective for TFIID complex formation in vivo.

Ranallo RT, Struhl K, Stargell LA.

Mol Cell Biol. 1999 Jun;19(6):3951-7.

Supplemental Content

Loading ...
Support Center